SXTC (China SXT Pharmaceuticals) Moat Score: 3/10 (As of Jul. 01, 2026)


SXTC China SXT Pharmaceuticals Inc SXTC
26 GF Score
Price $2.11
! 5 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Moat Score?

China SXT Pharmaceuticals SXTC +3.94% 26 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates SXTC with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 86.13% on this metric.

China SXT Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

China SXT Pharmaceuticals has No Moat: China SXT Pharmaceuticals Inc operates in a competitive pharmaceutical market with limited intellectual property and weak brand strength. The company faces significant competition and lacks durable cost advantages or regulatory barriers, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes China SXT Pharmaceuticals might have No Moat - Very weak/transient advantages.

China SXT Pharmaceuticals  (NAS:SXTC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

China SXT Pharmaceuticals Moat Score Related Terms

SXTC vs CABR, BFRI, BIOE: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Moat Score falls into.


SXTC
26GF Score
China SXT Pharmaceuticals Inc SXTC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
China SXT Pharmaceuticals (SXTC) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, China SXT Pharmaceuticals ranks #143 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is China SXT Pharmaceuticals' Moat Score too high?
China SXT Pharmaceuticals' current Moat Score is 3. Based on the distribution chart, China SXT Pharmaceuticals ranks #143 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Moat Score compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #143 out of 1031 companies for Moat Score. This places China SXT Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. China SXT Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (SXTC) has a current Moat Score of 3. The current Moat Score is 3. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China SXT Pharmaceuticals Business Description

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
26GF Score

Get the complete analysis for SXTC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.11
Price